Should I buy or sell Rocket Pharmaceuticals stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RCKT shares. View RCKT analyst ratings or view top-rated stocks .

What is Rocket Pharmaceuticals' stock price target for 2024?

9 Wall Street research analysts have issued twelve-month price objectives for Rocket Pharmaceuticals' stock. Their RCKT share price targets range from $35.00 to $65.00. On average, they anticipate the company's stock price to reach $50.38 in the next year. This suggests a possible upside of 91.4% from the stock's current price. View analysts price targets for RCKT or view top-rated stocks among Wall Street analysts .

How have RCKT shares performed in 2023?

Rocket Pharmaceuticals' stock was trading at $19.57 at the beginning of the year. Since then, RCKT stock has increased by 34.5% and is now trading at $26.32. View the best growth stocks for 2023 here .

When is Rocket Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024. View our RCKT earnings forecast .

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) issued its quarterly earnings results on Monday, November, 6th. The biotechnology company reported ($0.75) earnings per share for the quarter, beating analysts' consensus estimates of ($0.81) by $0.06. During the same period in the previous year, the business posted ($0.87) EPS.

What ETFs hold Rocket Pharmaceuticals' stock?

ETFs with the largest weight of Rocket Pharmaceuticals (NASDAQ:RCKT) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM) , Harbor Health Care ETF (MEDI) , Harbor Disruptive Innovation ETF (INNO) and Putnam BioRevolution ETF (SYNB) . Franklin Genomic Advancements ETF (HELX) .

What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX) , Pfizer (PFE) , SCYNEXIS (SCYX) , Sorrento Therapeutics (SRNE) , Amarin (AMRN) , Energy Transfer (ET) , Micron Technology (MU) , VBI Vaccines (VBIV) , Vaxart (VXRT) and Alibaba Group (BABA) .

Who are Rocket Pharmaceuticals' major shareholders?

Rocket Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (8.90%), Westfield Capital Management Co. LP (4.65%), Avidity Partners Management LP (1.76%), Bamco Inc. NY (1.23%), Assenagon Asset Management S.A. (1.09%) and JPMorgan Chase & Co. (0.85%). Insiders that own company stock include Gaurav Shah , Gotham Makker, John Militello, Jonathan David Schwartz, Kinnari Patel and Rtw Investments, Lp. View institutional ownership trends .

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Rocket Pharmaceuticals Stock Price, News & Analysis (NASDAQ:RCKT)

$25.92

+0.61 (+2.41%)

(As of 01:27 PM ET)

Compare

Today's Range: $25.10
▼
$26.55
50-Day Range: $16.78
▼
$25.31
52-Week Range: $14.89
▼
$26.55

Volume: 668,559 shs
Average Volume: 898,282 shs
Market Capitalization: $2.34 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $50.38

Rocket Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 91.4% Upside
$50.38 Price Target
Short Interest: Bearish
10.08% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.81
Upright™ Environmental Score
News Sentiment: 0.02
Based on 4 Articles This Week
Insider Trading: Selling Shares
$677,083 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.03) to ($2.70) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

223rd out of 949 stocks

Pharmaceutical Preparations Industry

87th out of 408 stocks

3.5

Analyst's Opinion

Consensus Rating
Rocket Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $50.38, Rocket Pharmaceuticals has a forecasted upside of 91.4% from its current price of $26.32.
Amount of Analyst Coverage
Rocket Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
10.08% of the outstanding shares of Rocket Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Rocket Pharmaceuticals has a short interest ratio ("days to cover") of 7.
Change versus previous month
Short interest in Rocket Pharmaceuticals has recently increased by 0.44%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Rocket Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Rocket Pharmaceuticals does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Rocket Pharmaceuticals has received a 74.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Rocket Pharmaceuticals is -0.81.

2.2

News and Social Media Coverage

News Sentiment
Rocket Pharmaceuticals has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Rocket Pharmaceuticals this week, compared to 9 articles on an average week.
Search Interest
12 people have searched for RCKT on MarketBeat in the last 30 days. This is an increase of 1,100% compared to the previous 30 days.
MarketBeat Follows
6 people have added Rocket Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Rocket Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $677,083.00 in company stock.
Percentage Held by Insiders
31.10% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
94.49% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Rocket Pharmaceuticals are expected to grow in the coming year, from ($3.03) to ($2.70) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Rocket Pharmaceuticals is -8.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Rocket Pharmaceuticals is -8.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Rocket Pharmaceuticals has a P/B Ratio of 4.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Rocket Pharmaceuticals Stock (NASDAQ:RCKT)

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. The company is headquartered in Cranbury, New Jersey.

RCKT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RCKT Stock News Headlines

December 5, 2023 | seekingalpha.com

Rocket Pharmaceuticals: Promising, But Not A Rocket At This Valuation

December 4, 2023 | yahoo.com

Guardians of the Galaxy Vol. 3’s Bradley Cooper Talks Personal Grief in Rocket Raccoon Performance

December 6, 2023 | Edge On The Street (Ad)

Energy Storage Trend Ignites Frenzy Over Vanadium Supply

As the world shifts to renewables such as wind and solar, how will we store all this energy? Vanadium batteries are the breakthrough that some experts predict will be the future of grid-scale energy storage. The problem is, only 5% of vanadium is mined in the U.S. - and China and Russia have a stranglehold on our supply.

December 4, 2023 | usnews.com

South Korea Tests Solid-Fuel Rocket Amid Space Race With North Korea

December 3, 2023 | americanbankingnews.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Trading Down 3.2%

November 28, 2023 | msn.com

Avenged Sevenfold to make stop at Cleveland's Rocket Mortgage FieldHouse in 2024

November 27, 2023 | msn.com

Laval Rocket Wanted More from Trip | Rocket Notepad

November 21, 2023 | usnews.com

Two Reporters, Third Person Killed in Rocket Strike Near Lebanon-Israel Border - State Media

December 6, 2023 | Financial Alphas (Ad)

Lithium Discovery So BIG You Can't Miss it, Even From Space

With the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!

November 10, 2023 | msn.com

Indie pop trio AJR coming to Rocket Mortgage FieldHouse in Summer 2024

November 9, 2023 | news.yahoo.com

Launch contracts are "basically worthless" until a rocket is proven and flying, Rocket Lab CEO says

November 9, 2023 | finance.yahoo.com

Wall Street Analysts See a 167.09% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High?

November 9, 2023 | yahoo.com

Kachow! Lightning McQueen is now in Rocket League

November 9, 2023 | msn.com

Lightning McQueen has Arrived to Rocket League

November 8, 2023 | techcrunch.com

Rocket Lab’s Electron launch vehicle “fully” booked next year, will resume flight as early as November-end

November 8, 2023 | markets.businessinsider.com

Positive 3Q Results and Robust Financial Position Drive Buy Rating for Rocket Pharmaceuticals with Increased 2024 Price Target

November 7, 2023 | markets.businessinsider.com

Rocket Pharmaceuticals: Promising Pivotal Studies, Undervalued Potential and Robust Financial Health Encourage Buy Rating

November 7, 2023 | yahoo.com

Rocket League Lightning McQueen DLC Revealed, Release Date Set

November 4, 2023 | msn.com

4 takeaways from chat with Rocket Companies exec on calling workers back to office

November 3, 2023 | msn.com

UToledo alumnus returns to Ohio to shoot debut feature film with help from another former Rocket

November 2, 2023 | msn.com

Rocket Companies ekes out 3rd quarter profit amid high mortgage rates

November 2, 2023 | msn.com

Geaux Rocket Ride becomes the second Breeders’ Cup horse to die in two days

November 2, 2023 | usatoday.com

Geaux Rocket Ride is second horse based at Santa Anita to die in lead up to Breeders' Cup

November 1, 2023 | msn.com

Haskell winner Geaux Rocket Ride euthanized after Breeders' Cup training injury

November 1, 2023 | sports.yahoo.com

Another step forward: Rocket Sanders bumped to likely for Florida game

October 28, 2023 | msn.com

Rocket Shut Out in Syracuse | RECAP: LAV @ SYR

October 28, 2023 | msn.com

Syracuse Crunch shut out Rocket, 5-0

See More Headlines

Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/06/2023
Today: 12/06/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/26/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RCKT
CUSIP: N/A
CIK: 1281895
Web: www.rocketpharma.com
Phone: (609) 659-8001
Fax: 646-224-9585
Employees: 240
Year Founded: 2018

Price Target and Rating

Average Stock Price Target: $50.38
High Stock Price Target: $65.00
Low Stock Price Target: $35.00
Potential Upside/Downside: +91.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.22)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-221,860,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -53.40%
Return on Assets: -47.51%

Debt

Debt-to-Equity Ratio: 0.04
Current Ratio: 13.35
Quick Ratio: 13.35

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.47 per share
Price / Book: 4.07

Miscellaneous

Outstanding Shares: 90,160,000
Free Float: 62,120,000
Market Cap: $2.37 billion
Optionable: Optionable
Beta: 1.02

Social Links

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Gaurav D. Shah M.D. (Age 48)
CEO & Director
Comp: $1.05M
Ms. Kinnari Patel M.B.A. (Age 44)
Pharm.D., President & COO
Comp: $849.93k
Mr. John C. Militello CPA (Age 50)
VP, Senior Controller, Treasurer, Principal Accounting Officer & Interim Principal Financial Officer
Comp: $501.42k
Mr. Mayo Pujols (Age 54)
Chief Technical Officer & Executive VP
Comp: $649.71k
Mr. Raj Prabhakar M.B.A. (Age 49)
Senior VP & Chief Business Officer
Comp: $619.13k
Mr. Martin Louis Wilson J.D. (Age 47)
General Counsel, Chief Compliance Officer & Senior VP
Comp: $149.95k
Kevin Giordano
Director of Corporate Communications
Ms. Isabel Carmona J.D.
Senior VP & Chief Human Resources Officer
Mr. Jonathan Schwartz M.D. (Age 58)
Chief Gene Therapy Officer & Senior VP of Clinical Development
Comp: $557.79k
Dr. Gayatri R. Rao J.D.
M.D., Chief Development Officer of LVV & Senior VP

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RCKT Stock Analysis - Frequently Asked Questions

Should I buy or sell Rocket Pharmaceuticals stock right now?: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RCKT shares.
View RCKT analyst ratings or view top-rated stocks.
What is Rocket Pharmaceuticals' stock price target for 2024?: 9 Wall Street research analysts have issued twelve-month price objectives for Rocket Pharmaceuticals' stock. Their RCKT share price targets range from $35.00 to $65.00. On average, they anticipate the company's stock price to reach $50.38 in the next year. This suggests a possible upside of 91.4% from the stock's current price.
View analysts price targets for RCKT or view top-rated stocks among Wall Street analysts.
How have RCKT shares performed in 2023?: Rocket Pharmaceuticals' stock was trading at $19.57 at the beginning of the year. Since then, RCKT stock has increased by 34.5% and is now trading at $26.32.
View the best growth stocks for 2023 here.
When is Rocket Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our RCKT earnings forecast.
How were Rocket Pharmaceuticals' earnings last quarter?: Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) issued its quarterly earnings results on Monday, November, 6th. The biotechnology company reported ($0.75) earnings per share for the quarter, beating analysts' consensus estimates of ($0.81) by $0.06. During the same period in the previous year, the business posted ($0.87) EPS.

What ETFs hold Rocket Pharmaceuticals' stock?: ETFs with the largest weight of Rocket Pharmaceuticals (NASDAQ:RCKT) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Harbor Health Care ETF (MEDI), Harbor Disruptive Innovation ETF (INNO) and Putnam BioRevolution ETF (SYNB).Franklin Genomic Advancements ETF (HELX).
What other stocks do shareholders of Rocket Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).
Who are Rocket Pharmaceuticals' major shareholders?: Rocket Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (8.90%), Westfield Capital Management Co. LP (4.65%), Avidity Partners Management LP (1.76%), Bamco Inc. NY (1.23%), Assenagon Asset Management S.A. (1.09%) and JPMorgan Chase & Co. (0.85%). Insiders that own company stock include Gaurav Shah, Gotham Makker, John Militello, Jonathan David Schwartz, Kinnari Patel and Rtw Investments, Lp.
View institutional ownership trends.
How do I buy shares of Rocket Pharmaceuticals?: Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:RCKT) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial